Przejdź do zawartości
Merck
  • Involvement of transcription factor XBP1s in the resistance of HDAC6 inhibitor Tubastatin A to superoxidation via acetylation-mediated proteasomal degradation.

Involvement of transcription factor XBP1s in the resistance of HDAC6 inhibitor Tubastatin A to superoxidation via acetylation-mediated proteasomal degradation.

Biochemical and biophysical research communications (2014-06-10)
Yue Zhang, Chang-mei Liu, Xian-cao Cao, Yi Zang, Yu-bo Zhou, Jia Li
ABSTRAKT

HDAC6 is a major cytoplasmic deacetylase. XBP1s is a basic-region leucine zipper (bZIP) transcriptional factor. Despite their mutual involvement in the anti-oxidative process, there are no reports about their inter-protein interactions so far. Here we identified a direct link between HDAC6 inhibition and XBP1s transcription activity in anti-oxidative damage. We showed that the specific HDAC6 inhibitor Tubastatin A could up-regulate XBP1s transcriptional activity, thereby increasing anti-oxidative genes expression. Moreover, knock down of XBP1s could significantly abolish the cell growth protection afforded by Tubastatin A. We hypothesize that Tubastatin A acts to increase XBP1s protein levels that are dependent on its HDAC6 deacetylase inhibition via a mechanism involving acetylation-mediated proteasomal degradation, providing novel mechanistic insight into the anti-oxidative effects of HDAC6 inhibition.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Valproic acid, European Pharmacopoeia (EP) Reference Standard
USP
Kwas walproinowy, United States Pharmacopeia (USP) Reference Standard
Supelco
Valproic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
2-Propylpentanoic acid
Valproic acid for system suitability, European Pharmacopoeia (EP) Reference Standard